The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancer.

ABSTRACT:

Background

Immune checkpoint inhibitors have aroused great expectation of tumor eradication. However, the effect of anti-PD-L1 treatment for cervical cancer is unsatisfactory and the underlying antagonist to anti-PD-L1 efficacy is remained to be studied. Here, we investigated the anti-tumor effect of anti-PD-L1 treatment in cervical tumor model and identified the antagonist to the therapeutic efficacy of anti-PD-L1 treatment.

Results

We found that PD-L1 exhibited a moderate expression in both cervical tumor cell lines and clinical samples compared to other tumor types and the para-tumor tissue respectively. Interestingly, our results showed that the anti-PD-L1 treated mice were dichotomously divided into responsive and unresponsive group after five cycles of anti-PD-L1 treat

SUBMITTER: Xu F 

PROVIDER: S-EPMC8414724 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature